IQVIA HLDGS INC (IQV) is drawing unusual attention today. Our newswire has captured 4 stories on IQV across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
IQVIA Holdings Inc. stock surged 13.94% to $242.94 in early trading on July 28, 2026, driven by the company's upbeat Q2 2026 earnings call and raised full-year guidance. The CEO highlighted strong organic growth, record R&D bookings, and AI-driven momentum, while the firm raised its 2026 revenue outlook to between $17.275 billion and $17.475 billion. The stock opened with a small 0.8% gap up but traded in a narrow range before settling near the low end of the session.
IQVIA's Q2 2026 earnings call underscored a strong performance across key metrics. The company reported adjusted earnings per share of $3.15, exceeding the $3.03 estimate, and revenue of $4.368 billion, beating the $4.301 billion forecast. The firm also announced a raised 2026 adjusted EPS guidance to $12.80 to $13. These results reflect robust R&D bookings and double-digit free cash flow growth, reinforcing confidence in the company’s long-term trajectory. The CEO emphasized AI traction and operational efficiency as key drivers of the improved outlook. Analysts from Baird, Barclays, and JPMorgan have raised price targets for the stock in recent days, reflecting the positive sentiment.
IQVIA has a market capitalization of $35.6 billion and a P/E ratio of 30.1. The stock has traded between $154.50 and $247.72 over the past 52 weeks, and its current price is near the upper end of that range. The stock opened at $244.99 and traded in a narrow range, reaching a high of $244.99 and a low of $243.41. Volume has been minimal, with no shares traded so far, compared to its 3-month average. Recent congressional trades include two sales by Rep. Ro Khanna and one by Donald J. Trump, though no purchases were reported in the last 90 days.
IQVIA has no scheduled earnings date in the immediate future, but investors will want to monitor coverage breadth as the raised guidance and analyst upgrades could attract further attention. The stock’s performance in the coming days will likely reflect the sustainability of the current momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
IQVIA Holdings Inc. analysis: clinical trials & healthcare data leader. Key risks—slowing guidance, CSMS weakness, regulatory threats. Click for an IQV update.
2026-07-28. The following slide deck was published by IQVIA Holdings Inc.
IQVIA Holdings (($IQV)) has held its Q2 earnings call. Read on for the main highlights of the call. IQVIA Holdings’ latest earnings call struck a clearly upbeat ton...
IQVIA (NYSE:IQV) reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted dil
IQVIA HLDGS INC (IQV) is drawing unusual attention today. Our newswire has captured 4 stories on IQV across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "IQVIA: A Great Business At The Wrong Price (Rating Downgrade)" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of IQV coverage reads 56/100 over 4 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on IQV: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IQV move explainers: 2026-07-29 · 2026-07-28 · 2026-07-23